Product Name: DYRKSubtide
Product Number: PE-01BHD95
Size: 1 mg      Price:97.00
5 mg      $US213.00
20 mg      389.00
Peptide Name: DYRKSubtide

Product Use: For assaying the phosphotransferase activity of Dual specificity tyrosine-phosphorylation-regulated kinase 1A (UniProt ID Q13627).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KRSRPASPRHKLG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1663.96 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid
Storage Conditions: -20°C

Peptide Recommended Enzyme: DYRK

Scientific Background: DYRK1A is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is a dual-specificity protein kinase that can phosphorylate tyrosine, serine, and threonine residues, as well as the proteins CRY2, FOXO1, SRSF6 and SIRT1. Phosphorylation at Y321 increases phosphotransferase activity. Phosphorylation at S529 also increases phosphotransferase activity and association with 14-3-3-beta. It is inhibited by RANBP9. It may play a role in cell proliferation pathways such as during brain development. DYRK1A has been found to prolong ERK activation via interactions with RAS, BRAF, and MEK1 and the formation of a RAS/BRAF/MEK1 complex. Overexpression in pheochromocytoma cells potentiated their neuronal differentiation in response to NGF through a RAS/MAPK signalling pathway. DYRK1A may also interact with viral oncoproteins such as adenovirus E1A and HPV-E7. Its role in cancer is unclear: inhibition of caspase-9 by DYRK1A protects mitotic cells from apoptosis, but overexpression attentuated calcineurin signalling, which leads to decreased angiogenesis and tumour growth. Active DYRK1A can induce megakaryocytic tumours (derived from bone marrow cells responsible for producing red blood cells).